Page last updated: 2024-12-07

7-nitro-1h-indole-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-nitro-1H-indole-2-carboxylic acid: acts on AP endonuclease, 3'-phosphodiesterase, and 3'-phosphatase activities of APE1; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID81409
CHEMBL ID1870764
SCHEMBL ID1277212
MeSH IDM0488808

Synonyms (46)

Synonym
einecs 230-154-6
1h-indole-2-carboxylic acid, 7-nitro-
7-nitroindole-2-carboxylic acid
6960-45-8
nsc69877
indole-2-carboxylic acid, 7-nitro-
nsc-69877
OPREA1_439132
crt0044876
dna base excision repair pathway inhibitor
MAYBRIDGE1_004786 ,
N-3300
STK503794
7-nitro-1h-indole-2-carboxylic acid
HMS555B12
AKOS005135879
A9205
NCGC00185073-01
NCGC00185073-02
7-nitroindole-2-carboxylicacid
EN300-49742
CHEMBL1870764 ,
nsc 69877
FT-0600788
S7449
BIUCOFQROHIAEO-UHFFFAOYSA-N
SCHEMBL1277212
DTXSID7064520
AC-33062
bdbm50030281
crt0044876, >=98% (hplc)
mfcd00044720
CCG-246292
HMS3653D05
nsc 69877,7-no2-ica
NCGC00185073-03
SW219854-1
AS-31463
AMY24828
A14304
CS-W015338
7-nitro-1h-indole-2-carboxylic acid.
dna base excision repair pathway
HY-W014622
SY005162
Z594271212

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Moreover, this class of compounds possesses a generally favorable in vitro ADME profile, along with good exposure levels in plasma and brain following intraperitoneal dosing (30 mg/kg body weight) in mice."( Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.
Dorjsuren, D; Jadhav, A; Maloney, DJ; Rai, G; Simeonov, A; Vyjayanti, VN; Wilson, DM, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
flap endonuclease 1Homo sapiens (human)Potency56.23410.133725.412989.1251AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency70.79460.050127.073689.1251AID588590
DNA polymerase kappa isoform 1Homo sapiens (human)Potency44.66840.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)IC50 (µMol)3.03000.05502.967710.0000AID1167344; AID1370978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ribonuclease TEscherichia coli K-12INH1,000.000010.000010.000010.0000AID1316273
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
telomere maintenanceDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repair, gap-fillingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA catabolic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA recombinationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of apoptotic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of mRNA stabilityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cell redox homeostasisDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
negative regulation of DNA-templated transcriptionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
telomere maintenance via base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA processingRibonuclease TEscherichia coli K-12
DNA damage responseRibonuclease TEscherichia coli K-12
tRNA processingRibonuclease TEscherichia coli K-12
rRNA 3'-end processingRibonuclease TEscherichia coli K-12
cellular response to UVRibonuclease TEscherichia coli K-12
tRNA 3'-end processingRibonuclease TEscherichia coli K-12
regulatory ncRNA 3'-end processingRibonuclease TEscherichia coli K-12
DNA replication proofreadingRibonuclease TEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
damaged DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded telomeric DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription coactivator activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription corepressor activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA-DNA hybrid ribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase I activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
uracil DNA N-glycosylase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
protein bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphoric diester hydrolase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5'-DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA exodeoxyribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5' exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
oxidoreductase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
site-specific endodeoxyribonuclease activity, specific for altered baseDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
chromatin DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
metal ion bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
class II DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strandsDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(abasic site) bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA 3'-5' DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5'-RNA exonuclease activityRibonuclease TEscherichia coli K-12
magnesium ion bindingRibonuclease TEscherichia coli K-12
nucleic acid bindingRibonuclease TEscherichia coli K-12
exonuclease activityRibonuclease TEscherichia coli K-12
RNA nuclease activityRibonuclease TEscherichia coli K-12
protein bindingRibonuclease TEscherichia coli K-12
single-stranded DNA 3'-5' DNA exonuclease activityRibonuclease TEscherichia coli K-12
3'-5' exonuclease activityRibonuclease TEscherichia coli K-12
RNA exonuclease activity, producing 5'-phosphomonoestersRibonuclease TEscherichia coli K-12
identical protein bindingRibonuclease TEscherichia coli K-12
protein homodimerization activityRibonuclease TEscherichia coli K-12
metal ion bindingRibonuclease TEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleolusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
mitochondrionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endoplasmic reticulumDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
centrosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
ribosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nuclear speckDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
perinuclear region of cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cytosolRibonuclease TEscherichia coli K-12
cytosolRibonuclease TEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1167344Inhibition of human APE1 after 25 mins by fluorescence assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development.
AID1316274Inhibition of 5'-[gamma-32P]ATP-labelled 11-nucleotide ssRNA binding to Caenorhabditis elegans GST-tagged CRN-4 expressed in Escherichia coli BL21 (DE3) pLysS at 1 mM preincubated for 10 mins followed by substrate addition measured after 20 mins by TBE ge2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).
AID1316272Inhibition of GST-tagged Caenorhabditis elegans CRN-4 exonuclease activity expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by [gamma-32P]ATP labelled 11-nucleotide ssRNA substrate addition for 30 mins by PAGE based autorad2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).
AID1316276Inhibition of 5'-[gamma-32P]ATP-labelled 11-nucleotide ssDNA binding to recombinant Escherichia coli K-12 N-terminal His-tagged RNase T expressed in Escherichia coli BL21-CodonPlus(DE3)-RIPL at 1 mM preincubated for 10 mins followed by substrate addition 2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).
AID1316278Inhibition of Lassa virus N-terminal His-tagged NP exonuclease domain (342 to 569 residues) expressed in Escherichia coli Tuner (DE3) using 3'-overhang 4-nucleotide stem-loop RNA preincubated for 10 mins followed by substrate addition measured after 60 mi2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).
AID1316273Inhibition of N-terminal His-tagged recombinant Escherichia coli K-12 RNase T exonuclease activity expressed in Escherichia coli BL21-CodonPlus(DE3)-RIPL preincubated for 10 mins followed by [gamma-32P]ATP labelled 11-nucleotide ssDNA substrate addition f2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).
AID672545Inhibition of human recombinant APE1 at 57 uM after 15 mins by fluorescence based HTS assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.
AID1370978Inhibition of APE1 in human HeLa cells assessed as reduction in AP site cleavage 5'-[gamma-32P]CTCGCAAGUGGGTACCGA-3' as substrate after 1 hr2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
AID1316277Inhibition of Lassa virus N-terminal His-tagged NP exonuclease domain (342 to 569 residues) expressed in Escherichia coli Tuner (DE3) using FAM-labeled 20-nucleotide ssRNA preincubated for 10 mins followed by substrate addition measured after 60 mins by P2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's11 (73.33)24.3611
2020's3 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]